Gli1 alone is sufficient to determine UGT1A-dependent cytarabine glucuronidation; thus, the inhibition of Gli1 by gene silencing or treatment with a Smo inhibitor (such as Vismodegib) sems to make AML cells mostly responsive to cytarabine [41,42]. This evidence concerns the gene SMO and acute myeloid leukemia.